Selegiline transdermal system in major depressive disorder
نویسندگان
چکیده
منابع مشابه
Selegiline transdermal system in major depressive disorder
125 ISSN 1758-2008 10.2217/NPY.12.9 © 2012 Future Medicine Ltd Neuropsychiatry (2012) 2(2), 125–134 Summary Selegiline transdermal system (STS) has been approved to treat major depressive disorder in the USA. STS represents a novel generation of monoamine oxidase inhibitors with a superior safety profile to older monoamine oxidase inhibitors, in particular with regard to food interactions. The ...
متن کاملTransdermal selegiline for the treatment of major depressive disorder
Non-selective inhibition of monoamine oxidase (MAO) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects. In the US, the selegiline transdermal system (STS; EMSAM) is the first antidepressant transdermal delivery system to receive Food and Drug Administration (FDA) approved labeling for the treatment of major depressive disorder (MDD). Cu...
متن کاملA critical appraisal of the selegiline transdermal system for major depressive disorder.
The selegiline transdermal system (STS) is the first antidepressant transdermal medication approved by the US FDA for the treatment of major depressive disorder. Its unique antidepressant delivery system allows for steady release of selegiline over 24 h with minimal fluctuation in drug serum levels. It is able to deliver high enough central nervous system concentrations required for an antidepr...
متن کاملThe Selegiline Transdermal System (Emsam)
212 P&T® • April 2008 • Vol. 33 No. 4 ABSTRACT Although monoamine oxidase inhib itors (MAOIs) at one time represented the mainstay of therapy for major depressive disorder (MDD), the risk of acute hypertensive reactions following the ingestion of tyramine-rich foods and the consequent need to restrict dietary tyramine represent a barrier to their use. In this article, we present an overview of ...
متن کاملA double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
BACKGROUND The monoamine oxidase (MAO) inhibitor selegiline has demonstrated antidepressant efficacy superior to placebo. A selegiline transdermal system (STS) has been developed with unique pharmacokinetic and pharmacodynamic properties that allow inhibition of central nervous system MAO-A and MAO-B enzymes while substantially avoiding inhibition of intestinal and liver MAO-A enzyme. This nove...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuropsychiatry
سال: 2012
ISSN: 1758-2008
DOI: 10.2217/npy.12.9